Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2019 07:00 ET | Source: Editas Medicine, Inc.; MaxCyte, Inc.

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies...
October 01, 2019 08:00 ET | Source: Editas Medicine, Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming...
August 29, 2019 08:00 ET | Source: Editas Medicine, Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following investor...
August 06, 2019 16:15 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2019 Results and Update

Cynthia (Cindy) Collins named President and Chief Executive Officer Initiated Brilliance Phase 1/2 clinical trial of EDIT-101(AGN-151587) for LCA10 Patient dosing in Brilliance trial on track for...
August 06, 2019 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine Appoints Cynthia Collins as President and Chief Executive Officer

CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has unanimously appointed...
July 30, 2019 16:02 ET | Source: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update

CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
July 25, 2019 09:00 ET | Source: Editas Medicine, Inc.; Allergan plc

Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10

Expect first patient dosing in second half of 2019 DUBLIN, Ireland and CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and...
June 15, 2019 11:30 ET | Source: Editas Medicine, Inc.

Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association

IND-enabling activities initiated for EDIT-301, a potentially best-in-class experimental medicine for the treatment of sickle cell disease and beta-thalassemia CAMBRIDGE, Mass., June 15, 2019 ...
May 07, 2019 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces First Quarter 2019 Results and Update

- Building on focus in oncology through newly-formed partnership with BlueRock Therapeutics to develop universal allogeneic cell medicines for cancer - - EDIT-101 (AGN-151587) for LCA10 on track for...
April 30, 2019 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update

CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...